This application is being submitted by Loyola University Chicago, Stritch School of Medicine, Cardinal Bernardin Cancer Center for renewal of this institution's long-standing participation as a site for the conduct of clinical trials under the umbrella of the Southwest Oncology Group (SWOG). Loyola remains a highly productive member of SWOG, enrolling 674 subjects to SWOG studies over the past 5 year grant cycle. Twenty-one members of the Division of Hematology/Oncology faculty are members of SWOG. Loyola's Departments of Radiation Oncology, Surgery, Thoracic Surgery, Urology, Gynecology and Pathology are active participants in SWOG-sponsored studies, identifying patients for inclusion in SWOG studies and for the subsequent treatment of these patients. The Clinical Research Office of the Cancer Center consists of 11 Registered Nurses, 4 Protocol Coordinators and 1 Regulatory Data Coordinator, who coordinate approximately 150 total clinical trials for all of the above disciplines. Loyola has four affiliate institutions participation in SWOG studies: Good Samaritan Hospital in Downers Grove, Illinois;Central DuPage Hospital in Winfield, Illinois, Edward Hospital in Naperville, Illinois, and Quad Cities CGOP in Davenport, lowa. Plans are underway to increase our commitment to SWOG during the next grant cycle both by increasing accruals with additional planned affiliates and increasing our scientific participation.

Public Health Relevance

The Southwest Oncology Group is one of the NCI's CTEP-supported cooperative groups which seek new and more effective therapies for cancer. PRINCIPAL INVESTIGATOR: Dr. Stiff is an experienced clinical researcher with a long-term commitment to SWOG programs. He is fully qualified for his role on this application. PROTECTION OF HUMAN SUBJECTS (Resume): ACCEPTABLE No concerns are evident. INCLUSION OF WOMEN PLAN (Resume): ACCEPTABLE Women account for 63% of all enrollments. No concerns are evident. INCLUSION OF MINORITIES PLAN (Resume): ACCEPTABLE Minority accrual could be improved. Hispanics represent 10% of accruals and African-Americans represent only 3% of accruals. They report a series of important efforts to increase accrual of minority populations including development of a position for a community outreach coordinator, the work of a physician liaison to the Hispanic community, the use of short form consents for non-English speakers, the use of patient navigators, the provision of low cost screening breast studies for the medically underserved, and offering studies to a broad geography across the Chicago area. Additional planning efforts to increase minority accrual are needed. INCLUSION OF CHILDREN PLAN (Resume): ACCEPTABLE Enrolled subjects are generally 18 years of age or older. OVERALL RECOMMENDATION: This application is rated 24 and is recommended for six years of support.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Loyola University Chicago
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2017) A Phase I/II Trial of Vorinostat (SAHA) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG S0806. Am J Hematol :
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465
Wozniak, Antoinette J; Moon, James; Thomas Jr, Charles R et al. (2015) A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer 16:340-7
Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8
Diefenbach, Catherine S; Li, Hailun; Hong, Fangxin et al. (2015) Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. Br J Haematol 171:530-8
Ramanathan, Ramesh K; McDonough, Shannon L; Kennecke, Hagen F et al. (2015) Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005). Cancer 121:2193-7

Showing the most recent 10 out of 228 publications